Abstract

Recent research in our lab has demonstrated a significant association between the incidence of subclinical mastitis and specific polymorphisms of the CXCR2 gene in Holstein dairy cows. This gene encodes a receptor for interleukin-8 (IL-8), a key regulator of neutrophil migration, killing and survival. Because of the importance of this gene in neutrophil function, we hypothesized that differences in neutrophil killing and survival may exist among the CXCR2 genotypes and potentially contribute to the observed variation in intramammary infections. To test this hypothesis, neutrophils were isolated from cows representing each CXCR2 +777 genotype (GG, GC or CC) and tested for suppression of apoptosis, reactive oxygen species (ROS) generation, glutathione levels, and bactericidal activity. A significant increase in survival was observed in neutrophils from cows with a CC genotype when compared to those with a GG genotype in response to IL-8, but not dexamethasone. In contrast, a significant reduction in neutrophil ROS generation in response to phorbol-13-myristate-12 acetate (PMA) was observed in cows with a CC genotype when compared to those with a GG genotype. However, no differences in bactericidal activity or glutathione levels were observed among genotypes. The functional activity of neutrophils from cows heterozygous for this polymorphism was intermediate between those with homozygous genotypes for those assays where differences were observed among homozygous genotypes. In summary, our results suggest that neutrophils from Holstein cows with different CXCR2 genotypes vary in their ability to suppress apoptosis and produce ROS. These differences have the potential to influence overall neutrophil function and may partially explain the variation observed with respect to mastitis in vivo. These results provide a foundation for future research aimed at better understanding the basic differences between dairy cows genetically more or less susceptible to mastitis and has the potential to provide novel preventive and therapeutic measures against inflammatory diseases such as mastitis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call